EuroPCR 2018 | OxAMI-PICSO: Coronary Sinus Occlusion, Improving Microvascular Function and Reducing Infarct Size

The index of microcirculatory resistance might guide therapy and controlled intermittent coronary sinus occlusions, improve microvascular function, and reduce infarct size.

OxAMI-PICSO: oclusión del seno coronario: mejorar la función microvascular y reducir el tamaño del infartoThis study included patients with prior ST-segment elevation myocardial infarction treated with primary angioplasty. Researchers measured the index of microcirculatory resistance before stenting and intermittent coronary sinus occlusion was used if the result was higher than 40. Control of this group was provided through a historical control cohort of patients with infarction and an index of microcirculatory resistance higher than 40. Infarct size was measured through magnetic resonance imaging (MRI) at 48 hours and at 6 months.

 

The study included a total of 105 patients (25 who underwent coronary sinus occlusion, 50 control patients whose index before primary angioplasty was >40, and 30 patients whose index was ≤40).


Read also: Swedish Registry on the SYNERGY DES: tested in primary PCI for the first time.


When compared with control patients, subjects who underwent intermittent coronary sinus occlusion exhibited smaller infarct size in the MRI at 48 hours and at 6 months.

 

Conclusion

Patients whose index of microcirculatory resistance is >40 before primary angioplasty might benefit from coronary sinus occlusion for the reduction of infarct size.

 

Original title: Index of Microcirculatory Resistance-Guided Therapy with Pressure-Controlled Intermittent Coronary Sinus Occlusion Improves Coronary Microvascular Function and Reduces Infarct Size in Patients with ST-Elevation Myocardial Infarction: The Oxford Acute Myocardial Infarction – Pressure-controlled Intermittent Coronary Sinus Occlusion Study (OxAMI-PICSO Study).

Presenter: Giovanni Luigi De Maria.

 

OxAMI-PICSO-presentación

OxAMI-PICSO-artículo-original


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Rotational atherectomy and its technical secrets: use of floppy or ES guidewire

Rotational atherectomy (RA) remains a very useful tool in the management of severe coronary calcification. However, many of its technical aspects rely more on...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...